Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Milveterol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 19/20 | 1.00 |
| ▸ | ADRB1 | P08588 | 5/20 | 1.00 |
| ▸ | ADRB3 | P13945 | 4/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Milveterol SCHEMBL168972 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1ADRB3 | |
| Milveterol SCHEMBL265695 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1ADRB3 | |
| Milveterol SCHEMBL185356 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1ADRB3 | |
| Milveterol SCHEMBL265694 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1ADRB3 | |
| Milveterol SCHEMBL29448200 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1ADRB3 | |
| Milveterol SCHEMBL2953766 | 0.99 | ADRB2 (0.98) | ADRB2ADRB1ADRB3 | |
| Milveterol SCHEMBL2953771 | 0.99 | ADRB2 (0.98) | ADRB2ADRB1ADRB3 | |
| Milveterol SCHEMBL2014102 | 0.99 | ADRB2 (0.98) | ADRB2ADRB1ADRB3 | |
| Milveterol SCHEMBL2014100 | 0.99 | ADRB2 (0.98) | ADRB2ADRB1ADRB3 | |
| Milveterol SCHEMBL2014099 | 0.99 | ADRB2 (0.98) | ADRB2ADRB1ADRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1856050-B1 | CRYSTALLINE FORMS OF A BIPHENYL COMPOUND | THERAVANCE INC (US) | 2009-11-25 | — | — | EP | claimed |
| US-7479562-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2009-01-20 | — | — | US | disclosed |
| US-20080269344-A1 | Beta2-Adrenergic Receptor Agonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2008-10-30 | — | — | US | disclosed |
| US-7427639-B2 | β2-adrenergic receptor agonists | THERAVANCE, INC. (US) | 2008-09-23 | — | — | US | disclosed |
| US-20070179179-A1 | Beta2-adrenergic receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2007-08-02 | — | — | US | disclosed |
| US-7217738-B2 | β2-adrenergic receptor agonists | THERAVANCE, INC. (US) | 2007-05-15 | — | — | US | disclosed |
| US-20060205946-A1 | Bronchodilators; treating chronic obstructive pulmonary disease or asthma; long duration of action; reduced side effects of dry-mouth and constipation; biphenyl carbamate derivatives; biphenyl-2-ylcarbamic acid 1-(3-(3-[3-(4-hydroxybenzylamino)propyl]-2-oxoimidazolidin-1-yl)propyl)piperidin-4-yl ester | THERAVANCE, INC. | 2006-09-14 | — | — | US | disclosed |
| US-20050261338-A1 | Beta2-adrenergic receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2005-11-24 | — | — | US | disclosed |
| US-6916961-B2 | β2-adrenergic receptor agonists | THERAVANCE, INC. (US) | 2005-07-12 | — | — | US | disclosed |
| EP-1235787-B1 | $g(b)2-ADRENERGIC RECEPTOR AGONISTS | THERAVANCE INC (US) | 2003-10-29 | — | — | EP | disclosed |
| US-6576793-B1 | β2-adrenergic receptor agonists | THERAVANCE, INC. | 2003-06-10 | — | — | US | disclosed |
| US-20030087307-A1 | Beta2-adrenergic receptor agonists | ADVANCED MEDICINE, INC. | 2003-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261338-A1 | Beta2-adrenergic receptor agonists | ADRB2, ADRB1, ADRA2B | ADRB2 1/4885ADRB1 2/4885ADRB3 4/4885 |
| US-20030087307-A1 | Beta2-adrenergic receptor agonists | ADRB2, ADRB1, ADRA2B | ADRB2 1/4885ADRB1 2/4885ADRB3 4/4885 |
| US-20060205946-A1 | Bronchodilators; treating chronic obstructive pulmonary disease or asthma; long duration of action; reduced side effects of dry-mouth and constipation; biphenyl carbamate derivatives; biphenyl-2-ylcarbamic acid 1-(3-(3-[3-(4-hydroxybenzylamino)propyl]-2-oxoimidazolidin-1-yl)propyl)piperidin-4-yl ester | CHRM3, CHRM2, CHRM1 | ADRB2 51/4885ADRB1 33/4885ADRB3 78/4885 |
| US-20080269344-A1 | Beta2-Adrenergic Receptor Agonists | ADRB2, ADRB1, ADRA2B | ADRB2 1/4885ADRB1 2/4885ADRB3 4/4885 |
| US-20070179179-A1 | Beta2-adrenergic receptor agonists | ADRB2, ADRB1, ADRA2B | ADRB2 1/4885ADRB1 2/4885ADRB3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.